Use of anthrax vaccine in the United States
Subtitle: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009
By: [prepared by Jennifer Gordon Wright ... [et.]]
Contributors: Centers for Disease Control and Prevention (U.S.); United States. Advisory Committee on Immunization Practices
Series: MMWR. Morbidity and mortality weekly report. Recommendations and reports -- v. 59, no. RR-6; Morbidity and mortality weekly report -- v. 59, no. RR-6.
Publisher: Dept. of Health and Human Services, Centers for Disease Control and Prevention
Published: 2010
Place of publication: Atlanta, GA
Language: eng
Number of pages: 30
Subjects: Administration & dosage; Anthrax; Vaccination; Standards; Contraindications; Anthrax Vaccines; Adverse effects; Prevention & control; Antibiotic Prophlyaxis
Description: "These recommendations from the Advisory Committee on Immunization Practices (ACIP) update the previous recommendations for anthrax vaccine adsorbed (AVA) (CDC. Use of anthrax vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 2000;49:1-20; CDC. Use of anthrax vaccine in response to terrorism: supplemental recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 2002;51:1024-6) and reflect the status of anthrax vaccine supplies in the United States. This statement 1) provides updated information on anthrax epidemiology; 2) summarizes the evidence regarding the effectiveness and efficacy, immunogenicity, and safety of AVA; 3) provides recommendations for pre-event and preexposure use of AVA; and 4) provides recommendations for postexposure use of AVA. In certain instances, recommendations that did not change were clarified. No new licensed anthrax vaccines are presented. Substantial changes to these recommendations include the following: 1) reducing the number of doses required to complete the pre-event and preexposure primary series from 6 doses to 5 doses, 2) recommending intramuscular rather than subcutaneous AVA administration for preexposure use, 3) recommending AVA as a component of postexposure prophylaxis in pregnant women exposed to aerosolized Bacillus anthracis spores, 4) providing guidance regarding preexposure vaccination of emergency and other responder organizations under the direction of an occupational health program, and 5) recommending 60 days of antimicrobial prophylaxis in conjunction with 3 doses of AVA for optimal protection of previously unvaccinated persons after exposure to aerosolized B. anthracis spores"--P. 1.
Notes: Cover title.

"July 23, 2010."

"U.S. Government Printing Office: 2010-623-026/41261, Region IV"--P. [4] of cover.

Includes bibliographical references (p. 23-29).

Also available via the World Wide Web.